

**CURRENT LISTING OF CLAIMS**

25. (Previously Presented) A conjugate comprising Substance P, or an analog thereof, and a polypeptide that inhibits protein synthesis, wherein the analog is selected from CYGGGGGGGRPKPQQFF SarLMet(O<sub>2</sub>)-amide (SEQ ID NO:1) and CYGGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).
26. (Previously Presented) The conjugate of claim 25, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGGRPKPQQFF SarLMet(O<sub>2</sub>)-amide (SEQ ID NO:1).
27. (Previously Presented) The conjugate of claim 25, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).
28. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P or analog thereof through a disulfide linkage.
29. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is saporin.
30. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.
31. (Previously Presented) The conjugate of claim 30, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.
32. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a toxin.

33. (Previously Presented) The conjugate of claim 32, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.

34. (Previously Presented) The conjugate of claim 32, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

35. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 25, and a pharmaceutically acceptable carrier.

36. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 29, and a pharmaceutically acceptable carrier.